TrialHealth and quality of life outcomes2018

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).

Sender Herschorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.